RxDoctor Payments Data

Stephen Dalton, MD

Dermatology · Novato, CANPI 1053318824

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 106 payments — averaging $12.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$663
  • Novartis$126
  • Boehringer Ingelheim$82
  • Pfizer$71
  • Sanofi$57
  • Lilly USA, LLC$55
  • plus $278 from 12 others

What the payments were for

  • Food & beverage$1,30398%
  • Education$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 40th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$946,023
Medicare patients
1,316
Services billed
12,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$393,206
OtezlaApremilast11$53,137
OpzeluraRuxolitinib Phosphate13$33,429
Fluocinonide182$7,463
Halobetasol Propionate80$4,164
Alclometasone Dipropionate133$4,126
Calcipotriene26$3,750
Azelaic Acid39$3,714
Ketoconazole221$3,132
Clobetasol Propionate46$2,775
Metronidazole49$2,294
Mupirocin258$2,141
CiclopiroxCiclopirox Olamine130$1,933
Imiquimod53$1,650
Desonide30$1,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$13$53,13711 claims
Incyte CorporationOpzelura$30$33,42913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,875 dermatology providers in California.

Other dermatology in Novato

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →